Comparative Effectiveness of Umeclidinium/Vilanterol versus Inhaled Corticosteroid/Long-Acting β₂-Agonist in Patients with Chronic Obstructive Pulmonary Disease in a Primary Care Setting in England

References

• World Health Organisation. The top 10 causes of death; 2022. Available from: https://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed November, 2022.
   Google Scholar
• British Lung Foundation. Chronic obstructive pulmonary disease (COPD) statistics. Available from: https://statistics.blf.org.uk/copd. Accessed September, 2022.
   Google Scholar
• Miravitlles M, Ribera A. Understanding the impact of symptoms on the burden of COPD. Respir Res. 2017;18(1):67. doi:10.1186/s12931-017-0548-3
   PubMed Web of Science ®Google Scholar
• Shah CH, Onukwugha E, Zafari Z, Villalonga-Olives E, Park J-E, Slejko JF. Economic burden of comorbidities among COPD patients hospitalized for acute exacerbations: an analysis of a commercially insured population. Expert Rev Pharmacoecon Outcomes Res. 2022;22(4):683–690. doi:10.1080/14737167.2021.1981291
   PubMed Web of Science ®Google Scholar
• Davis JR, Wu B, Kern DM, et al. Impact of nonadherence to inhaled corticosteroid/LABA therapy on COPD exacerbation rates and healthcare costs in a commercially insured US population. Am Health Drug Benefits. 2017;10(2):92–102.
   PubMed Web of Science ®Google Scholar
• Mäkelä MJ, Backer V, Hedegaard M, Larsson K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir Med. 2013;107(10):1481–1490. doi:10.1016/j.rmed.2013.04.005
   PubMed Web of Science ®Google Scholar
• Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441. doi:10.1016/j.rmed.2010.09.006
   PubMed Web of Science ®Google Scholar
• Albrecht JS, Khokhar B, Huang TY, et al. Adherence and healthcare utilization among older adults with COPD and depression. Respir Med. 2017;129:53–58. doi:10.1016/j.rmed.2017.06.002
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63(9):831–838. doi:10.1136/thx.2007.086041
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD; 2022. Available from: https://goldcopd.org/2022-gold-reports-2/. Accessed September, 2022.
   Google Scholar
• National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2018. Available from: https://www.nice.org.uk/guidance/ng115/resources/chronic-obstructive-pulmonary-disease-in-over-16s-diagnosis-and-management-pdf-66141600098245. Accessed September, 2022.
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD; 2023. Available from: https://goldcopd.org/2023-gold-report-2/. Accessed December, 2022.
   Google Scholar
• Electronic medicines compendium. ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed. Available from: https://www.medicines.org.uk/emc/medicine/28949#gref. Accessed September, 2022.
   Google Scholar
• Moretz C, Cole AL, Mu G, et al. Evaluation of medication adherence and rescue medication use in non-exacerbating patients with COPD receiving umeclidinium/vilanterol or budesonide/formoterol as initial maintenance therapy. Int J Chron Obstruct Pulmon Dis. 2020;15:2207–2215. doi:10.2147/copd.s259850
   PubMed Web of Science ®Google Scholar
• Moretz C, Sharpsten L, Bengtson LG, et al. Real-world effectiveness of umeclidinium/vilanterol versus fluticasone propionate/salmeterol as initial maintenance therapy for chronic obstructive pulmonary disease (COPD): a retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:1721–1737. doi:10.2147/copd.s204649
   PubMed Web of Science ®Google Scholar
• Kalhan R, Slade D, Ray R, et al. Umeclidinium/vilanterol compared with fluticasone propionate/ salmeterol, budesonide/ formoterol, and tiotropium as initial maintenance therapy in patients with COPD who have high costs and comorbidities. Int J Chron Obstruct Pulmon Dis. 2021;16:1149–1161. doi:10.2147/copd.s298032
   PubMed Web of Science ®Google Scholar
• Herbert A, Wijlaars L, Zylbersztejn A, Cromwell D, Hardelid P. Data resource profile: hospital Episode Statistics Admitted Patient Care (HES APC). Int J Epidemiol. 2017;46(4):1093–1093i. doi:10.1093/ije/dyx015
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Thomas SL, et al. Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. Clin Epidemiol. 2016;8:771. doi:10.2147/CLEP.S117867
   PubMed Web of Science ®Google Scholar
• Rothnie KJ, Müllerová H, Hurst JR, et al. Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records. PLoS One. 2016;11(3):e0151357. doi:10.1371/journal.pone.0151357
   PubMed Web of Science ®Google Scholar
• Chesnaye NC, Stel VS, Tripepi G, et al. An introduction to inverse probability of treatment weighting in observational research. Clin Kidney J. 2022;15(1):14–20. doi:10.1093/ckj/sfab158
   PubMed Web of Science ®Google Scholar
• Austin PC. Goodness-of-fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score. Pharmacoepidemiol Drug Saf. 2008;17(12):1202–1217. doi:10.1002/pds.1673
   PubMed Web of Science ®Google Scholar
• van Boven JF, Chavannes NH, van der Molen T, Rutten-van Molken MP, Postma MJ, Vegter S. Clinical and economic impact of non-adherence in COPD: a systematic review. Respir Med. 2014;108(1):103–113. doi:10.1016/j.rmed.2013.08.044
   PubMed Web of Science ®Google Scholar
• Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64(11):939–943. doi:10.1136/thx.2009.113662
   PubMed Web of Science ®Google Scholar
• Gregoriano C, Dieterle T, Breitenstein AL, et al. Does a tailored intervention to promote adherence in patients with chronic lung disease affect exacerbations? A randomized controlled trial. Respir Res. 2019;20(1):273. doi:10.1186/s12931-019-1219-3
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Stanford RH, Parker ED, Reinsch TK, Buikema AR, Blauer-Peterson C. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA. Respir Med. 2019;150:1–7. doi:10.1016/j.rmed.2019.01.019
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922. doi:10.2147/COPD.S130482
   PubMed Web of Science ®Google Scholar
• Punekar YS, Sharma S, Pahwa A, Takyar J, Naya I, Jones PW. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. Respir Res. 2017;18(1):86. doi:10.1186/s12931-017-0566-1
   PubMedGoogle Scholar
• Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58(4):323–337. doi:10.1016/j.jclinepi.2004.10.012
   PubMed Web of Science ®Google Scholar
• Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86(4):304–314. doi:10.4065/mcp.2010.0575
   PubMed Web of Science ®Google Scholar
• Wolf A, Dedman D, Campbell J, et al. Data resource profile: Clinical Practice Research Datalink (CPRD) aurum. Int J Epidemiol. 2019;48(6):1740–1740g. doi:10.1093/ije/dyz034
   PubMed Web of Science ®Google Scholar
• Nissen F, Morales DR, Mullerova H, Smeeth L, Douglas IJ, Quint JK. Validation of asthma recording in the Clinical Practice Research Datalink (CPRD). BMJ Open. 2017;7(8):e017474. doi:10.1136/bmjopen-2017-017474
   PubMed Web of Science ®Google Scholar
• Quint JK, Mullerova H, DiSantostefano RL, et al. Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). BMJ Open. 2014;4(7):e005540. doi:10.1136/bmjopen-2014-005540
   PubMed Web of Science ®Google Scholar